TY - CHAP
T1 - Glycosphingolipids and insulin resistance
AU - Aerts, Johannes M F G
AU - Boot, Rolf G.
AU - Van Eijk, Marco
AU - Groener, J.
AU - Bijl, N.
AU - Lombardo, E.
AU - Bietrix, F.M.
AU - Dekker, N.
AU - Groen, A.K.
AU - Ottenhoff, R.
AU - Van Roomen, C.
AU - Aten, J.
AU - Serlie, M.
AU - Langeveld, M.
AU - Wennekes, T.
AU - Overkleeft, H.S.
PY - 2011
Y1 - 2011
N2 - Glycosphingolipids are structural membrane components, residing largely in the plasma membrane with their sugar-moieties exposed at the cell’s surface. In recent times a crucial role for glycosphingolipids in insulin resistance has been proposed. A chronic state of insulin resistance is a rapidly increasing disease condition in Western and developing countries. It is considered to be the major underlying cause of the metabolic syndrome, a combination of metabolic abnormalities that increases the risk for an individual to develop Type 2 diabetes, obesity, cardiovascular disease, polycystic ovary syndrome and nonalcoholic fatty liver disease. As discussed in this chapter, the evidence for a direct regulatory interaction of glycosphingolipids with insulin signaling is still largely indirect. However, the recent finding in animal models that pharmacological reduction of glycosphingolipid biosynthesis ameliorates insulin resistance and prevents some manifestations of metabolic syndrome, supports the view that somehow glycosphingolipids act as critical regulators, Importantly, since reductions in glycosphingolipid biosynthesis have been found to be well tolerated, such approaches may have a therapeutic potential.
AB - Glycosphingolipids are structural membrane components, residing largely in the plasma membrane with their sugar-moieties exposed at the cell’s surface. In recent times a crucial role for glycosphingolipids in insulin resistance has been proposed. A chronic state of insulin resistance is a rapidly increasing disease condition in Western and developing countries. It is considered to be the major underlying cause of the metabolic syndrome, a combination of metabolic abnormalities that increases the risk for an individual to develop Type 2 diabetes, obesity, cardiovascular disease, polycystic ovary syndrome and nonalcoholic fatty liver disease. As discussed in this chapter, the evidence for a direct regulatory interaction of glycosphingolipids with insulin signaling is still largely indirect. However, the recent finding in animal models that pharmacological reduction of glycosphingolipid biosynthesis ameliorates insulin resistance and prevents some manifestations of metabolic syndrome, supports the view that somehow glycosphingolipids act as critical regulators, Importantly, since reductions in glycosphingolipid biosynthesis have been found to be well tolerated, such approaches may have a therapeutic potential.
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-80053591938&partnerID=MN8TOARS
U2 - 10.1007/978-1-4614-0650-1_7
DO - 10.1007/978-1-4614-0650-1_7
M3 - Chapter
SN - 978-1-4614-0649-5
T3 - Sphingolipids and Metabolic Disease
SP - 99
EP - 119
BT - Sphingolipids and Metabolic Disease
PB - Springer
ER -